Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 2,879.50 -32.50 -1.12% -21.54%
Acadia Pharmaceuticals 19.20 0.36 1.91% -66.19%
Acorda Therapeutics 2.60 -0.09 -3.35% 302.23%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Biogen 235.74 -0.37 -0.16% -3.05%
Cara Therapeutics 13.18 0.60 4.77% -10.28%
GW Pharmaceuticals 218.96 0 0% 108.53%
Halozyme Therapeutics 32.88 -0.40 -1.20% -19.03%
Ionis Pharmaceuticals 27.45 -1.60 -5.51% -45.68%
Intra Cellular Therapies 40.48 -0.45 -1.10% 69.37%
Eli Lilly 248.04 -6.79 -2.66% 70.40%
Marinus Pharmaceuticals 11.11 0.10 0.91% -30.08%
Neurocrine Biosciences 83.25 -1.49 -1.76% -12.21%
Novartis 73.44 -0.80 -1.08% -9.75%
Ultragenyx Pharmaceutical 75.23 1.52 2.06% -35.91%
UCB 96.14 -0.90 -0.93% 9.35%
Vertex Pharmaceuticals 186.94 -3.17 -1.67% -18.83%


Aptinyx Inc
Aptinyx Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which are focused on brain and nervous system functions. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and Lewy body dementia.